Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gensight BiologicsGSGTF Earnings Yield (Joel Greenblatt) % is -27.40% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 1,321 Biotechnology companies, Gensight Biologics ranks worse than 71.61% on this metric.
Gensight Biologics's Enterprise Value for the quarter that ended in Dec. 2025 was $54.12 Mil.
Gensight Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-10.62 Mil. Gensight Biologics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was -27.40%.
The historical rank and industry rank for Gensight Biologics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
GSGTF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -118.72 Med: -41.59 Max: -11.04
Current: -30.96
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Gensight Biologics was -11.04%. The lowest was -118.72%. And the median was -41.59%.
GSGTF's Earnings Yield (Joel Greenblatt) % is ranked worse than 71.61% of 1321
companies
in the Biotechnology industry
Industry Median: -10.21
vs GSGTF: -30.96
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Gensight Biologics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Gensight Biologics Earnings Yield (Joel Greenblatt) % Related Terms
Gensight Biologics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Gensight Biologics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gensight Biologics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Gensight Biologicss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of -27.40% mean?
Gensight Biologics (GSGTF) has a Earnings Yield (Joel Greenblatt) % of -27.40% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #946 out of 1321 companies in the Biotechnology industry, placing it in the top 71.6%.
Is Gensight Biologics' Earnings Yield (Joel Greenblatt) % too high?
Gensight Biologics' current Earnings Yield (Joel Greenblatt) % is -27.40%. Based on the distribution chart, Gensight Biologics ranks #946 out of 1321 companies in the Biotechnology industry, which is below the industry midpoint.
How does Gensight Biologics' Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #946 out of 1321 companies for Earnings Yield (Joel Greenblatt) %. This places Gensight Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current Earnings Yield (Joel Greenblatt) % is -27.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The current Earnings Yield (Joel Greenblatt) % is -27.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current Earnings Yield (Joel Greenblatt) % is -27.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GSGTF has been successfully added to your 
